# Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

> **NCT07385846** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Jennifer Leddon** · enrollment: 8 (estimated)

## Conditions studied

- Glioblastoma
- Mismatch Repair Deficiency

## Interventions

- **DRUG:** Pembrolizumab
- **DEVICE:** Navifus Focused Ultrasound Sonification

## Key facts

- **NCT ID:** NCT07385846
- **Lead sponsor:** Jennifer Leddon
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-06-01
- **Final completion:** 2030-06-01
- **Target enrollment:** 8 (ESTIMATED)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07385846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07385846, "Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07385846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*